Protein Expression and Libraries Facility
蛋白质表达和文库设施
基本信息
- 批准号:8378498
- 负责人:
- 金额:$ 16.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AccountingAffinityAliquotAntibiotic ResistanceAntibodiesAntibody FormationArchivesAreaBacteriaBaculovirusesBasic Cancer ResearchBiological AssayBiological ProcessBuffersCancer CenterCancer Research ProjectCell Culture TechniquesCell LineCell Surface ProteinsCell WallCellsCharacteristicsChimeric ProteinsChromatographyCleaved cellCloningCloning VectorsCollectionComplementary DNAConsultConsultationsCrystallizationCulture MediaCustomCytomegalovirusDNA Restriction EnzymesDNA Sequence AnalysisDNA-Directed RNA PolymeraseDerivation procedureDestinationsDetectionDetergentsDevelopmentDigestionDrug resistanceEngineeringEnsureEpitopesEscherichia coliExpression LibraryFactor XFacultyFluorescence MicroscopyFreezingGene DeliveryGene ExpressionGenerationsGenesGeneticGenetic VariationGenomic LibraryGlutathione S-TransferaseGoalsGoldGrowthGuidelinesHealthcareHis-His-His-His-His-HisHistidineHuman ResourcesHybridomasImmunizationIn VitroInclusion BodiesIncubatorsIndividualInfectionInsectaIsopropyl ThiogalactosideKineticsLibrariesLifeMaintenanceMammalian CellMembraneMethodologyMicroscopyMolecular Sieve ChromatographyMonitorMusN-terminalNucleic AcidsOne-Step dentin bonding systemPeptide HydrolasesPeptide Signal SequencesPerformancePlasmidsPreparationProceduresProcessProductionProtein SecretionProteinsProtocols documentationQuality ControlRNA InterferenceRecombinant DNARecombinant ProteinsRecombinantsResearch PersonnelResourcesRetroviral VectorRetroviridaeRoleSamplingScientistScreening procedureSepharoseServicesSite-Directed MutagenesisSonicationSourceStandardizationStructureStructure-Activity RelationshipSubfamily lentivirinaeSystemTechnologyTemperatureTetracyclinesThrombinTrainingTransfectionTransfer RNAUbiquitin CVesicular stomatitis Indiana virusViralVirionVirusWestern BlottingYeastsaerosolizedanticancer researchassay developmentbasecDNA Expressioncancer stem cellcell typeexperienceexpression vectorgel electrophoresishigh throughput screeningimprovedin vivoinstrumentinterestloss of functionmeetingsmemberparticleplasmid DNApolypeptidepreventpromoterprotein expressionprotein foldingprotein purificationquality assurancereceptorrecombinant virusrepositoryresearch studysmall hairpin RNAsmall moleculesmall molecule librariesstable cell linestem cell populationtechnology developmenttissue culturetrioctyl phosphine oxidevector
项目摘要
The Protein Expression and Libraries Facility (Protein Expression) provides Cancer Center members
efficient and expert technical assistance in recombinant DMA plasmid engineering, protein expression in
bacteria and baculovirus-infected insect cells, purification of recombinant proteins to homogeneity, and
production of high-titer stocks of retroviruses (e.g. lentiviruses) for delivery of shRNA and cDNAs to
mammalian cells. The Facility has expertise in all aspects of vector technology for protein expression,
baculovirus generation, recombinant protein expression, and affinity and conventional chromatography
approaches to protein purification, and production of infectious lenti-/retroviruses. The proteins produced by
the facility must be of high quality and purity in order to be used by Cancer Center scientists to achieve a
wide range of experimental objectives, such as characterization of enzymatic activities, crystallization for
structural analysis, characterization of structure-function relationships of protein:protein, protein:nucleic acid,
and protein:small molecule interactions; development of assays for small molecule high throughput
screening; and immunization of mice to generate custom antibodies utilizing the Hybridoma Facility. The
facility will continue to expand it's repertoire of vectors available for protein expression, included high titer
retroviral vectors, acquire RNAi libraries, and implement a new assay development service for highthroughput
screening of small molecule libraries. The facility personnel are highly trained technical experts in
all areas of the proposed support services to be provided to the individual projects. The centralization and
standardization of these practices under the direction of very experienced staff allows for high-throughput
expression plasmid construction and large-volume protein expression services, including quality assurance
and control procedures to ensure efficient, consistent production and purification of high quality recombinant
proteins. The Facility also maximizes biosafety by confining retrovirus (e.g. lentivirus) production to a
centralized biosafety level 2 (BSL2) unit, which prevents aerosolization of viruses from contaminating
incubators and parental cultures of cell lines, and improves quality control in the production of virus stocks to
be used in gain- and loss-of-function experiments in vitro and in vivo. Currently the Facility is being
expanded to accommodate the storage and handling of viral libraries, additional purification instruments, and
the rapid assay systems to meet Cancer Center needs.
蛋白质表达和文库设施(蛋白质表达)提供癌症中心成员
重组DMA质粒工程,蛋白质表达的高效和专家技术援助
细菌和杆状病毒感染的昆虫细胞,将重组蛋白纯化为同质性,并
生产逆转录病毒(例如慢病毒)将SHRNA和CDNA递送至
哺乳动物细胞。该设施在向量技术的各个方面都有专业知识,用于蛋白质表达,
杆状病毒的产生,重组蛋白表达以及亲和力和常规色谱
蛋白质纯化的方法和感染性的毛逆转录病毒的产生。由
该设施必须具有高质量和纯度,才能被癌症中心科学家使用以实现
广泛的实验目标,例如酶活性的表征,结晶
结构分析,蛋白质结构功能关系的表征:蛋白质,蛋白质:核酸,
和蛋白质:小分子相互作用;开发小分子高通量的测定
筛选;并通过杂交瘤静止剂进行自定义抗体进行免疫接种。这
设施将继续扩大其可用于蛋白质表达的向量的曲目,包括高滴度
逆转录病毒载体,获取RNAi库并实施新的测定开发服务
筛选小分子库。设施人员是受过训练的技术专家
拟议的支持服务的所有领域都将提供给各个项目。集中化和
在经验丰富的员工的指导下,这些实践的标准化允许高通量
表达质粒构建和大量蛋白质表达服务,包括质量保证
和控制程序,以确保高质量重组的有效,一致的产生和纯化
蛋白质。该设施还通过将逆转录病毒(例如慢病毒)生产限制为生物安全性
集中式生物安全级2(BSL2)单元,可防止病毒的气化
细胞系的孵化器和父母培养物,并改善病毒库存生产的质量控制
用于体外和体内的功能丧失实验。目前的设施正在
扩展以适应病毒库的存储和处理,额外的净化工具以及
快速测定系统以满足癌症中心的需求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL M LIEBERMAN其他文献
PAUL M LIEBERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL M LIEBERMAN', 18)}}的其他基金
Project 4: Regulation of EBV Latency and Oncogenesis by Hypoxia
项目4:缺氧对EBV潜伏期和肿瘤发生的调节
- 批准号:
10714176 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Epigenomic Drivers of EBV Epithelial Cancers
EB 病毒上皮癌的表观基因组驱动因素
- 批准号:
10627690 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers
针对 EB 病毒上皮癌的表观遗传和代谢控制
- 批准号:
10627689 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL
EBNA1 抑制剂用于治疗 EBV 阳性 DLBCL
- 批准号:
10719866 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Drugging EBNA1 to Treat EBV-Associated Cancers - Diversity Supplement
使用 EBNA1 药物治疗 EBV 相关癌症 - Diversity Supplement
- 批准号:
10818976 - 财政年份:2021
- 资助金额:
$ 16.15万 - 项目类别:
Drugging EBNA1 to Treat EBV-Associated Cancers
药物 EBNA1 治疗 EBV 相关癌症
- 批准号:
10185459 - 财政年份:2021
- 资助金额:
$ 16.15万 - 项目类别:
Regulation of EBV Latency by Purine Metabolism and Signaling
通过嘌呤代谢和信号传导调节 EBV 潜伏期
- 批准号:
10298045 - 财政年份:2021
- 资助金额:
$ 16.15万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Connexin Distribution in Physiological Versus Pathological Cardiac Hypertrophy
生理性与病理性心脏肥大中的连接蛋白分布
- 批准号:
8195558 - 财政年份:2009
- 资助金额:
$ 16.15万 - 项目类别:
Connexin Distribution in Physiological Versus Pathological Cardiac Hypertrophy
生理性与病理性心脏肥大中的连接蛋白分布
- 批准号:
7903963 - 财政年份:2009
- 资助金额:
$ 16.15万 - 项目类别: